{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% confidence interval could not be estimated because of the small number of patients who had an event (17 patients had died by the cutoff date).","groupId":"OG000","lowerLimit":"18.10","upperLimit":"NA","value":"33.4"},{"comment":"The median and 95% confidence interval could not be estimated because of the small number of patients who had an event (13 patients had died by the cutoff date).","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the initial dose of vismodegib until death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.","id":"OG000","title":"Metastatic Basal-Cell Carcinoma"},{"description":"Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.","id":"OG001","title":"Locally Advanced Basal-Cell Carcinoma"}],"paramType":"MEDIAN","populationDescription":"Efficacy-evaluable population: All treated patients for whom the independent pathologist's interpretation of archival tissue or baseline biopsies was consistent with basal cell carcinoma.","reportingStatus":"POSTED","timeFrame":"From the initial dose of study drug until death from any cause (up to the clinical cutoff date of 30 May 2013, up to 4 years)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}